Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Retained Earnings (2016 - 2025)

Historic Retained Earnings for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $8.2 billion.

  • United Therapeutics' Retained Earnings rose 1837.48% to $8.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 billion, marking a year-over-year increase of 1837.48%. This contributed to the annual value of $7.2 billion for FY2024, which is 1982.88% up from last year.
  • Latest data reveals that United Therapeutics reported Retained Earnings of $8.2 billion as of Q3 2025, which was up 1837.48% from $7.9 billion recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Retained Earnings registered a high of $8.2 billion during Q3 2025, and its lowest value of $3.9 billion during Q1 2021.
  • Its 5-year average for Retained Earnings is $5.7 billion, with a median of $5.5 billion in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 1170.97% in 2021, then surged by 1988.38% in 2024.
  • Over the past 5 years, United Therapeutics' Retained Earnings (Quarter) stood at $4.3 billion in 2021, then grew by 16.86% to $5.0 billion in 2022, then increased by 19.53% to $6.0 billion in 2023, then increased by 19.83% to $7.2 billion in 2024, then rose by 13.44% to $8.2 billion in 2025.
  • Its Retained Earnings stands at $8.2 billion for Q3 2025, versus $7.9 billion for Q2 2025 and $7.5 billion for Q1 2025.